Related Experiment Video

Updated: May 21, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Raf kinase inhibitor protein (RKIP) in cancer

June Escara-Wilke1, Kam Yeung, Evan T Keller

  • 1Department of Urology, University of Michigan, RM 5308 Cancer Center, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA.

Cancer Metastasis Reviews
|June 12, 2012
PubMed

Insights

Raf kinase inhibitory protein (RKIP) acts as a metastasis suppressor, with its reduced expression linked to cancer spread and therapy resistance. Restoring RKIP function may offer new cancer treatment strategies.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Raf kinase inhibitory protein (RKIP) was first identified as phosphatidylethanolamine binding protein.
  • RKIP inhibits Raf kinase activation of MEK and modulates NF-κB and G-protein signaling pathways.

Purpose of the Study:

  • To investigate the role of RKIP in cancer metastasis and therapeutic resistance.
  • To determine if RKIP functions as a metastasis suppressor gene.

Main Methods:

  • Gene array screening comparing metastatic and non-metastatic prostate cancer cell lines.
  • Analysis of RKIP expression in metastatic versus non-metastatic tissues across multiple cancers.

Main Results:

  • RKIP expression was found to be low in metastatic prostate cancer cells compared to non-metastatic cells.
  • RKIP expression is downregulated in metastatic tissues across various cancers, indicating a broad role in metastasis.
  • Loss of RKIP confers radioresistance and chemoresistance, impacting therapeutic efficacy.

Conclusions:

  • RKIP functions as a metastasis suppressor gene.
  • Downregulation of RKIP is a common mechanism contributing to cancer metastasis.
  • Understanding RKIP's role is crucial for developing novel therapeutic strategies to combat cancer metastasis and enhance treatment outcomes.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...